Gefitinib Completed Phase 2 Trials for Metastatic Cancers / Lung Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00452244Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
NCT00411047Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT01530334Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
NCT00193336Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
NCT00238251Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
NCT00217698Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00103051Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
NCT00068653Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
NCT00062062Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
NCT00188617Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
NCT02142036N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy